Seeking Alpha
26 Aug 2026, 20:15 UTC · 8w ago
Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts
Impact · against what's priced in
NUVB faces downward pressure as a massive discrepancy emerges between management's $3.8bn peak revenue target and analyst estimates of $650m. This valuation gap, combined with sequential declines in patient starts, suggests the recent 200% price run may have overshot the drug's actual growth trajectory.
- NUVB−0.40
No priced-in read yet
- In context
The market is facing a reality check as analyst peak revenue estimates for Ibtrozi (~$650m) are drastically lower than management's $3.8bn projection, while sequential patient starts have begun to decline.
Read from the article alone
Top 1 mover · tap to explore
